Literature DB >> 24150220

Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.

T Hideshima1, R Mazitschek2, L Santo3, N Mimura1, G Gorgun1, P G Richardson1, N Raje3, K C Anderson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24150220      PMCID： PMC4405100          DOI： 10.1038/leu.2013.301

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress.

Authors:  Yoshiharu Kawaguchi; Jeffrey J Kovacs; Adam McLaurin; Jeffery M Vance; Akihiro Ito; Tso Pang Yao
Journal:  Cell       Date:  2003-12-12       Impact factor: 41.582

2.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authors:  Loredana Santo; Teru Hideshima; Andrew L Kung; Jen-Chieh Tseng; David Tamang; Min Yang; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Walter C Ogier; Diana Cirstea; Scott Rodig; Homare Eda; Tyler Scullen; Miriam Canavese; James Bradner; Kenneth C Anderson; Simon S Jones; Noopur Raje
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

3.  Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.

Authors:  Naoya Mimura; Mariateresa Fulciniti; Gullu Gorgun; Yu-Tzu Tai; Diana Cirstea; Loredana Santo; Yiguo Hu; Claire Fabre; Jiro Minami; Hiroto Ohguchi; Tanyel Kiziltepe; Hiroshi Ikeda; Yutaka Kawano; Maureen French; Martina Blumenthal; Victor Tam; Nathalie L Kertesz; Uriel M Malyankar; Mark Hokenson; Tuan Pham; Qingping Zeng; John B Patterson; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-04-26       Impact factor: 22.113

4.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authors:  Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

5.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

Authors:  Teru Hideshima; James E Bradner; Jason Wong; Dharminder Chauhan; Paul Richardson; Stuart L Schreiber; Kenneth C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

6.  Catalysis of lysine 48-specific ubiquitin chain assembly by residues in E2 and ubiquitin.

Authors:  Monica C Rodrigo-Brenni; Scott A Foster; David O Morgan
Journal:  Mol Cell       Date:  2010-08-27       Impact factor: 17.970

7.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Authors:  Enrique M Ocio; David Vilanova; Peter Atadja; Patricia Maiso; Edvan Crusoe; Diego Fernández-Lázaro; Mercedes Garayoa; Laura San-Segundo; Teresa Hernández-Iglesias; Enrique de Alava; Wenlin Shao; Yung-Mae Yao; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

8.  Chemical phylogenetics of histone deacetylases.

Authors:  James E Bradner; Nathan West; Melissa L Grachan; Edward F Greenberg; Stephen J Haggarty; Tandy Warnow; Ralph Mazitschek
Journal:  Nat Chem Biol       Date:  2010-02-07       Impact factor: 15.040

9.  Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.

Authors:  A Z Badros; R Vij; T Martin; J A Zonder; L Kunkel; Z Wang; S Lee; A F Wong; R Niesvizky
Journal:  Leukemia       Date:  2013-01-31       Impact factor: 11.528

10.  Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.

Authors:  A J Jakubowiak; D S Siegel; T Martin; M Wang; R Vij; S Lonial; S Trudel; V Kukreti; N Bahlis; M Alsina; A Chanan-Khan; F Buadi; F J Reu; G Somlo; J Zonder; K Song; A K Stewart; E Stadtmauer; B L Harrison; A F Wong; R Z Orlowski; S Jagannath
Journal:  Leukemia       Date:  2013-05-14       Impact factor: 11.528
View more
  7 in total

1.  Progress and Paradigms in Multiple Myeloma.

Authors:  Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

2.  Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.

Authors:  Teru Hideshima; Jun Qi; Ronald M Paranal; Weiping Tang; Edward Greenberg; Nathan West; Meaghan E Colling; Guillermina Estiu; Ralph Mazitschek; Jennifer A Perry; Hiroto Ohguchi; Francesca Cottini; Naoya Mimura; Güllü Görgün; Yu-Tzu Tai; Paul G Richardson; Ruben D Carrasco; Olaf Wiest; Stuart L Schreiber; Kenneth C Anderson; James E Bradner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

Review 3.  Novel therapeutic strategies for multiple myeloma.

Authors:  Naoya Mimura; Teru Hideshima; Kenneth C Anderson
Journal:  Exp Hematol       Date:  2015-06-26       Impact factor: 3.084

Review 4.  Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.

Authors:  Takeshi Harada; Teru Hideshima; Kenneth C Anderson
Journal:  Int J Hematol       Date:  2016-04-20       Impact factor: 2.490

5.  Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.

Authors:  T Hideshima; F Cottini; H Ohguchi; J Jakubikova; G Gorgun; N Mimura; Y-T Tai; N C Munshi; P G Richardson; K C Anderson
Journal:  Blood Cancer J       Date:  2015-05-15       Impact factor: 11.037

6.  DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Authors:  Angelique Bruyer; Ken Maes; Laurie Herviou; Alboukadel Kassambara; Anja Seckinger; Guillaume Cartron; Thierry Rème; Nicolas Robert; Guilhem Requirand; Stéphanie Boireau; Carsten Müller-Tidow; Jean-Luc Veyrune; Laure Vincent; Salahedine Bouhya; Hartmut Goldschmidt; Karin Vanderkerken; Dirk Hose; Bernard Klein; Elke De Bruyne; Jerome Moreaux
Journal:  Br J Cancer       Date:  2018-03-02       Impact factor: 7.640

Review 7.  The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.

Authors:  Maria Cosenza; Samantha Pozzi
Journal:  Int J Mol Sci       Date:  2018-08-09       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.